Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01 ...

STAFFORD, Texas - Greenwich LifeSciences, Inc. (NASDAQ:GLSI), a clinical-stage biopharmaceutical company valued at $163 million, has announced the commencement of analysis on the open label HLA data ...

Analysis of the open label data from FLAMINGO-01 has commenced and has been conducted in a manner that maintains the study blind. A preliminary review of FLAMINGO-01 HLA data in both the HLA-A*02 ...

Greenwich LifeSciences (GLSI) announced an update on FLAMINGO-01 open label HLA data. Analysis of the open label data from FLAMINGO-01 has ...

Reveal insider sentiment with alternative data that tracks buy and sell trades made by top managers and company directors.

Greenwich LifeSciences, Inc.'s main program, GLSI-100, faces challenges in proving its benefit over existing HER2-positive breast cancer treatments, with ongoing phase 3 trial results expected by ...

Featured here, the Balance Sheet for Greenwich Lifesciences Inc, which summarizes the company's financial position including assets, liabilities and shareholder equity for each of the latest 10 period ...

Greenwich LifeSciences, Inc. announced progress in its Phase III clinical trial FLAMINGO-01, which is studying its immunotherapy GLSI-100 to prevent breast cancer recurrences. The European ...

FLAMINGO-01 (NCT05232916) is a Phase III clinical trial designed to evaluate the safety and efficacy of GLSI-100 (GP2 + GM-CSF) in HER2 positive breast cancer patients who had residual disease or ...